½ÃÀ庸°í¼­
»óǰÄÚµå
1539393

»ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2031³â)

Bioresorbable Vascular Scaffold Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Persistence Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 170 Pages | ¹è¼Û¾È³» : 2-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Persistence Market Research´Â À̹ø¿¡ »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ¼¼°è ½ÃÀå¿¡ °üÇÑ Á¾ÇÕ º¸°í¼­¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÃËÁø¿äÀΡ¤µ¿Ç⡤±âȸ¡¤°úÁ¦¸¦ Æ÷ÇÔÇÑ Áß¿äÇÑ ½ÃÀå ¿ªÇÐÀ» öÀúÇÏ°Ô Æò°¡Çϰí, ½ÃÀå ±¸Á¶¿¡ °üÇÑ »ó¼¼ÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ÀλçÀÌÆ®

  • »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå ±Ô¸ð(2024³â) : 3¾ï 3,900¸¸ ´Þ·¯
  • ¿¹Ãø ½ÃÀå ¼ö·®(2031³â) : 5¾ï 9,280¸¸ ´Þ·¯
  • ¼¼°è ½ÃÀå ¼ºÀå·ü(CAGR 2024-2031³â) : 8.3%

»ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå - Á¶»ç ¹üÀ§

»ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå´Â °ü»óµ¿¸Æ Áúȯ Ä¡·á¿¡ »ç¿ëµÇ´Â Çõ½ÅÀûÀÎ ÀÇ·á±â±âÀÔ´Ï´Ù. ÀÌ ½ºÄ³Æúµå´Â Ç÷°üÀ» ÀϽÃÀûÀ¸·Î ±¸Á¶ÀûÀ¸·Î ÁöÁöÇÏ°í ½Ã°£ÀÌ Áö³²¿¡ µû¶ó Á¡Â÷ÀûÀ¸·Î ¿ëÇØµÇµµ·Ï ¼³°èµÇ¾î ¿µ±¸ÀûÀÎ ÀÓÇöõÆ®°¡ ÇÊ¿äÇÏÁö ¾Ê½À´Ï´Ù. ÀÌ ½ÃÀåÀº º´¿ø, ½ÉÀå ¼¾ÅÍ, Àü¹® Ŭ¸®´ÐÀ» ´ë»óÀ¸·Î Çϸç, Æú¸®¸Ó ±â¹Ý, ±Ý¼Ó ±â¹Ý, ÇÏÀ̺긮µå ½ºÄ³Æúµå µî ´Ù¾çÇÑ À¯ÇüÀÇ ½ºÄ³Æúµå¸¦ Á¦°øÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, ½ºÄ³Æúµå Àç·á ¹× µðÀÚÀÎÀÇ ¹ßÀü, ÃÖ¼Ò Ä§½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù.

½ÃÀå ¼ºÀåÀÇ ÃËÁø¿äÀÎ:

¼¼°è »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀåÀº ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, Ç÷°ü Ä¡À¯¸¦ Áö¿øÇÏ´Â È¿°úÀûÀ̰í ÀϽÃÀûÀÎ ¼Ö·ç¼ÇÀÇ Çʿ伺 µî ¸î °¡Áö ÁÖ¿ä ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. »õ·Î¿î »ýü Àç·áÀÇ °³¹ß ¹× ½ºÄ³Æúµå µðÀÚÀÎÀÇ °³¼±°ú °°Àº ±â¼ú ¹ßÀüÀº Ä¡·á °á°ú¿Í ȯÀÚÀÇ ¾ÈÀü¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÃÖ¼Òħ½ÀÀû ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í ½ÉÇ÷°ü Ä¡·á °³¼±À» À§ÇÑ Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·ÂÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ :

À¯¸ÁÇÑ ¼ºÀå Àü¸Á¿¡µµ ºÒ±¸Çϰí, »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀåÀº ³ôÀº ºñ¿ë°ú Á¦ÇÑµÈ º¸Çè Àû¿ë ¹üÀ§¶ó´Â ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. »ýÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå¿¡ ÇÊ¿äÇÑ º¹ÀâÇÑ Á¦Á¶ °øÁ¤°ú °í±Þ Àç·á´Â ºñ¿ë »ó½ÂÀÇ ¿øÀÎÀÌ µÉ ¼ö ÀÖÀ¸¸ç, ƯÈ÷ ½ÅÈï ±¹°¡¿¡¼­´Â ½ÃÀå µµÀÔÀÇ À庮ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÃÀå¿¡¼­´Â Àå±âÀûÀÎ ¼º´É°ú »ýüÀûÇÕ¼º°ú °ü·ÃµÈ ±ÔÁ¦Àû Àå¾Ö¹° ¹× ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Á¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇϱâ À§Çؼ­´Â Áö¼ÓÀûÀÎ Çõ½Å, ºñ¿ë °ü¸® Àü·«, ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ ¹× Á¤Ã¥ ÀÔ¾ÈÀÚ¿ÍÀÇ Çù·ÂÀÌ ÇÊ¿äÇÕ´Ï´Ù.

½ÃÀå ±âȸ

»ýüÈí¼ö¼º Ç÷°ü½ºÄ³Æúµå ½ÃÀåÀº ±â¼ú Çõ½Å°ú ¿ëµµ È®´ë·Î ÀÎÇØ Å« ¼ºÀå ±âȸ¸¦ ¸ÂÀÌÇϰí ÀÖ½À´Ï´Ù. »õ·Î¿î Æú¸®¸Ó ¹× »ýüȰ¼º ÄÚÆÃÀÇ °³¹ß µî »õ·Î¿î ½ºÄ³Æúµå Àç·áÀÇ ½ÅÈï ±¹°¡ ½ÃÀå °³Ã´Àº ½ÃÀå È®´ëÀÇ »õ·Î¿î ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. ¸»ÃÊÇ÷°ü ÁßÀç¼ú¿¡¼­ »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³ÆúµåÀÇ Ã¤Åà Áõ°¡¿Í ¿ø°Ý ¸ð´ÏÅ͸µ ¹× °³ÀÎÈ­µÈ Ä¡·á °èȹ°ú °°Àº µðÁöÅÐ Çコ ±â¼úÀÇ ÅëÇÕÀº ȯÀÚ °á°ú¸¦ °³¼±ÇÏ°í ½ÃÀå ¹üÀ§¸¦ ³ÐÈ÷°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇÏ°í ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀåÀ» °¡¼ÓÇϱâ À§Çؼ­´Â Àü·«Àû ÆÄÆ®³Ê½Ê, R&D ÅõÀÚ, ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼Ç äÅÃÀÌ ÇʼöÀûÀÔ´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

  • »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀåÀÇ ¼¼°è ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
  • ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼­ »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³ÆúµåÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ´Â ½ºÄ³ÆúµåÀÇ À¯Çü°ú ¿ëµµ´Â ¹«¾ùÀΰ¡?
  • ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ »ýüÈí¼ö¼º Ç÷°ü½ºÄ³Æúµå ½ÃÀå °æÀï ±¸µµ´Â ¾î¶»°Ô º¯È­Çϰí Àִ°¡?
  • »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ±â¾÷Àº ¾îµðÀ̸ç, ½ÃÀå °ü·Ã¼ºÀ» À¯ÁöÇϱâ À§ÇØ ¾î¶² Àü·«À» äÅÃÇϰí Àִ°¡?
  • ¼¼°è »ýüÈí¼ö¼º Ç÷°ü½ºÄ³Æúµå ½ÃÀåÀÇ »õ·Î¿î µ¿Çâ°ú Àü¸ÁÀº?

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå ½ÃÀå °³¿ä

  • ½ÃÀåÀÇ ¹üÀ§¿Í Á¤ÀÇ
  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀÎ
    • ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • ÁÖ¿ä µ¿Çâ
  • °Å½Ã°æÁ¦ ¿äÀÎ
    • ¼¼°èÀÇ ºÎ¹®º° Àü¸Á
    • ¼¼°èÀÇ GDP ¼ºÀå Àü¸Á
    • ¼¼°èÀÇ ÇコÄɾî ÁöÃâ Àü¸Á
  • COVID-19ÀÇ ¿µÇ⠺м®
  • ¿¹Ãø ¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ

Á¦3Àå ºÎ°¡°¡Ä¡ ÀλçÀÌÆ®

  • Á¦Ç° äÅà ºÐ¼®
  • Áúº´ ¿ªÇÐ
  • ±â¼ú Æò°¡
  • ±ÔÁ¦ »óȲ
  • °ø±Þ¸Á ºÐ¼®
  • ÁÖ¿ä °Å·¡¿Í ÇÕº´
  • PESTLE ºÐ¼®
  • Porter's Five Forces ºÐ¼®

Á¦4Àå °¡°Ý ºÐ¼®, 2024³â

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • Á¦Ç° °¡°Ý¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎ
  • °¡°Ý ºÐ¼® : Á¦Ç°º°
  • Áö¿ªº° °¡°Ý°ú Á¦Ç° ¼±È£µµ

Á¦5Àå ¼¼°èÀÇ »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå Àü¸Á : ½ÇÀû(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
    • ½ÃÀå ¼ö·®(´ÜÀ§) ¿¹Ãø
    • ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í Àü³â´ëºñ ¼ºÀå·ü
    • Àý´ë¾× ±âȸ
  • ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯) ºÐ¼®°ú ¿¹Ãø
    • °ú°Å ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯) ºÐ¼®, 2019-2023³â
    • ÇöÀç ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, 2024-2031³â
  • ¼¼°èÀÇ »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå Àü¸Á : Á¦Ç°
    • ¼­·Ð/ÁÖ¿ä Á¶»ç °á°ú
    • °ú°Å ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯) ºÐ¼®, Á¦Ç°º°, 2019-2023³â
    • ÇöÀç ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¼ö·®(´ÜÀ§) ºÐ¼®°ú ¿¹Ãø, Á¦Ç°º°, 2024-2031³â
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Á¦Ç°
  • ¼¼°èÀÇ »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå Àü¸Á : ¿ëµµ
    • ¼­·Ð/ÁÖ¿ä Á¶»ç °á°ú
    • °ú°Å ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯) ºÐ¼®, ¿ëµµº°, 2019-2023³â
    • ÇöÀç ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, ¿ëµµº°, 2024-2031³â
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ¿ëµµ
  • ¼¼°èÀÇ »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå Àü¸Á : ÃÖÁ¾»ç¿ëÀÚ
    • ¼­·Ð/ÁÖ¿ä Á¶»ç °á°ú
    • °ú°Å ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯) ºÐ¼®, ÃÖÁ¾»ç¿ëÀÚº°, 2019-2023³â
    • ÇöÀç ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, ÃÖÁ¾»ç¿ëÀÚº°, 2024-2031³â
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚ

Á¦6Àå ¼¼°èÀÇ »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå Àü¸Á : Áö¿ª

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • °ú°Å ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯) ºÐ¼®, Áö¿ªº°, 2019-2023³â
  • ÇöÀç ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, Áö¿ªº°, 2024-2031³â
    • ºÏ¹Ì
    • À¯·´
    • µ¿¾Æ½Ã¾Æ
    • ³²¾Æ½Ã¾Æ¡¤¿À¼¼¾Æ´Ï¾Æ
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Áö¿ª

Á¦7Àå ºÏ¹ÌÀÇ »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå Àü¸Á : ½ÇÀû(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)

Á¦8Àå À¯·´ÀÇ »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå Àü¸Á : ½ÇÀû(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)

Á¦9Àå µ¿¾Æ½Ã¾ÆÀÇ »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå Àü¸Á : ½ÇÀû(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)

Á¦10Àå ³²¾Æ½Ã¾Æ¡¤¿À¼¼¾Æ´Ï¾ÆÀÇ »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå Àü¸Á : ½ÇÀû(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)

Á¦11Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå Àü¸Á : ½ÇÀû(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)

Á¦12Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ »ýüÈí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå Àü¸Á : ½ÇÀû(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â
  • ½ÃÀå ±¸Á¶
    • °æÀï °ÝÈ­ ¸Ê : ½ÃÀ庰
    • °æÀï ´ë½Ãº¸µå
  • ±â¾÷ °³¿ä(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±Ù µ¿Çâ)
    • Meril Life Sciences Pvt. Ltd.
    • Zeus Company LLC
    • Biotronik
    • Abbott
    • MicroPort Scientific Corporation
    • Kyoto Medical
    • Elixir Medical(MedImpact Healthcare Systems, Inc.)
    • Cigna
    • B. Braun Melsungen AG
    • Boston Scientific Corporation
    • REVA Medical

Á¦14Àå ºÎ·Ï

  • Á¶»ç ¹æ¹ý
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç
  • µÎÀÚ¾î¿Í ¾à¾î
KSA 24.09.23

Persistence Market Research has recently released a comprehensive report on the worldwide market for bioresorbable vascular scaffolds. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

  • Bioresorbable Vascular Scaffold Market Size (2024E): US$339.0 Mn
  • Projected Market Value (2031F):US$592.8 Mn
  • Global Market Growth Rate (CAGR 2024 to 2031):8.3%

Bioresorbable Vascular Scaffold Market - Report Scope:

Bioresorbable vascular scaffolds are innovative medical devices used in the treatment of coronary artery disease. These scaffolds are designed to provide temporary structural support to blood vessels and gradually dissolve over time, eliminating the need for permanent implants. The market caters to hospitals, cardiac centers, and specialized clinics, offering a range of scaffold types including polymer-based, metal-based, and hybrid scaffolds. Market growth is driven by increasing prevalence of cardiovascular diseases, advancements in scaffold materials and design, and rising demand for minimally invasive procedures.

Market Growth Drivers:

The global bioresorbable vascular scaffold market is propelled by several key factors, including the growing incidence of cardiovascular diseases and the need for effective and temporary solutions to support vessel healing. Technological advancements, such as the development of new biomaterials and improved scaffold designs, are enhancing treatment outcomes and patient safety. The rising preference for minimally invasive procedures is also driving demand for bioresorbable scaffolds. Additionally, increasing investments in research and development and favorable government initiatives aimed at improving cardiovascular care are further fueling market growth.

Market Restraints:

Despite promising growth prospects, the bioresorbable vascular scaffold market faces challenges related to high cost and limited reimbursement coverage. The complex manufacturing process and the advanced materials required for bioresorbable scaffolds contribute to higher costs, which can be a barrier to market adoption, especially in emerging economies. Moreover, the market encounters regulatory hurdles and safety concerns associated with long-term performance and biocompatibility of scaffolds. Addressing these challenges requires ongoing innovation, cost management strategies, and collaboration with healthcare providers and policymakers.

Market Opportunities:

The bioresorbable vascular scaffold market presents significant growth opportunities driven by technological innovations and expanding applications. Advances in scaffold materials, such as the development of novel polymers and bioactive coatings, are opening new avenues for market expansion. The increasing adoption of bioresorbable scaffolds in peripheral vascular interventions and the integration of digital health technologies, such as remote monitoring and personalized treatment plans, are enhancing patient outcomes and broadening market scope. Strategic partnerships, investment in R&D, and the introduction of cost-effective solutions are essential to capitalize on these opportunities and drive sustained market growth.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the bioresorbable vascular scaffold market globally?
  • Which scaffold types and applications are driving bioresorbable scaffold adoption across different healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the bioresorbable vascular scaffold market?
  • Who are the key players contributing to the bioresorbable vascular scaffold market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global bioresorbable vascular scaffold market?

Competitive Intelligence and Business Strategy:

Leading players in the global bioresorbable vascular scaffold market, including Abbott Laboratories, Boston Scientific Corporation, and Medtronic PLC, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced scaffolds with improved biocompatibility, strength, and degradation profiles. Collaborations with research institutions, healthcare providers, and regulatory agencies facilitate market access and promote technology adoption. Emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances patient outcomes in the evolving bioresorbable vascular scaffold landscape.

Key Companies Profiled:

  • Meril Life Sciences Pvt. Ltd.
  • Zeus Company LLC
  • Biotronik
  • Abbott
  • MicroPort Scientific Corporation
  • Kyoto Medical
  • Elixir Medical (MedImpact Healthcare Systems, Inc.)
  • Cigna
  • B. Braun Melsungen AG
  • Boston Scientific Corporation
  • REVA Medical

Bioresorbable Vascular Scaffold Market Segmentation

By Product

  • Metal Bioresorbable Vascular Scaffold
  • Polymer Bioresorbable Vascular Scaffold

By Application

  • Peripheral Artery
  • Coronary Artery

By End User

  • Hospitals
  • Ambulatory Care Centers
  • Cardiac Centers

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Bioresorbable Vascular Scaffold Market Snapshot, 2024-2031
  • 1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
    • 2.3.3. Global Healthcare Spending Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Disease Epidemiology
  • 3.3. Technology Assessment
  • 3.4. Regulatory Landscape
  • 3.5. Supply Chain Analysis
  • 3.6. Key Deals and Mergers
  • 3.7. PESTLE Analysis
  • 3.8. Porter's Five Force Analysis

4. Price Analysis, 2024

  • 4.1. Key Highlights
  • 4.2. Key Factors Impacting Product Prices
  • 4.3. Pricing Analysis, By Product
  • 4.4. Regional Prices and Product Preferences

5. Global Bioresorbable Vascular Scaffold Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 5.1. Key Highlights
    • 5.1.1. Market Volume (Units) Projections
    • 5.1.2. Market Size (US$ Bn) and Y-o-Y Growth
    • 5.1.3. Absolute $ Opportunity
  • 5.2. Market Size (US$ Bn) Analysis and Forecast
    • 5.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
    • 5.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2031
  • 5.3. Global Bioresorbable Vascular Scaffold Market Outlook: Product
    • 5.3.1. Introduction / Key Findings
    • 5.3.2. Historical Market Size (US$ Bn) Analysis, By Product, 2019-2023
    • 5.3.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Product, 2024-2031
      • 5.3.3.1. Metal Bioresorbable Vascular Scaffold
      • 5.3.3.2. Polymer Bioresorbable Vascular Scaffold
  • 5.4. Market Attractiveness Analysis: Product
  • 5.5. Global Bioresorbable Vascular Scaffold Market Outlook: Application
    • 5.5.1. Introduction / Key Findings
    • 5.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2023
    • 5.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
      • 5.5.3.1. Peripheral Artery
      • 5.5.3.2. Coronary Artery
  • 5.6. Market Attractiveness Analysis: Application
  • 5.7. Global Bioresorbable Vascular Scaffold Market Outlook: End User
    • 5.7.1. Introduction / Key Findings
    • 5.7.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2023
    • 5.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
      • 5.7.3.1. Hospitals
      • 5.7.3.2. Ambulatory Care Centers
      • 5.7.3.3. Cardiac Centers
      • 5.7.3.4. Others
  • 5.8. Market Attractiveness Analysis: End User

6. Global Bioresorbable Vascular Scaffold Market Outlook: Region

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
    • 6.3.1. North America
    • 6.3.2. Europe
    • 6.3.3. East Asia
    • 6.3.4. South Asia and Oceania
    • 6.3.5. Latin America
    • 6.3.6. Middle East & Africa
  • 6.4. Market Attractiveness Analysis: Region

7. North America Bioresorbable Vascular Scaffold Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Application
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 7.3.1. U.S.
    • 7.3.2. Canada
  • 7.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Product, 2024-2031
    • 7.4.1. Metal Bioresorbable Vascular Scaffold
    • 7.4.2. Polymer Bioresorbable Vascular Scaffold
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
    • 7.5.1. Peripheral Artery
    • 7.5.2. Coronary Artery
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 7.6.1. Hospitals
    • 7.6.2. Ambulatory Care Centers
    • 7.6.3. Cardiac Centers
    • 7.6.4. Others
  • 7.7. Market Attractiveness Analysis

8. Europe Bioresorbable Vascular Scaffold Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Application
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 8.3.1. Germany
    • 8.3.2. France
    • 8.3.3. U.K.
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Russia
    • 8.3.7. Turkey
    • 8.3.8. Rest of Europe
  • 8.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Product, 2024-2031
    • 8.4.1. Metal Bioresorbable Vascular Scaffold
    • 8.4.2. Polymer Bioresorbable Vascular Scaffold
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
    • 8.5.1. Peripheral Artery
    • 8.5.2. Coronary Artery
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 8.6.1. Hospitals
    • 8.6.2. Ambulatory Care Centers
    • 8.6.3. Cardiac Centers
    • 8.6.4. Others
  • 8.7. Market Attractiveness Analysis

9. East Asia Bioresorbable Vascular Scaffold Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Application
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. South Korea
  • 9.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Product, 2024-2031
    • 9.4.1. Metal Bioresorbable Vascular Scaffold
    • 9.4.2. Polymer Bioresorbable Vascular Scaffold
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
    • 9.5.1. Peripheral Artery
    • 9.5.2. Coronary Artery
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 9.6.1. Hospitals
    • 9.6.2. Ambulatory Care Centers
    • 9.6.3. Cardiac Centers
    • 9.6.4. Others
  • 9.7. Market Attractiveness Analysis

10. South Asia & Oceania Bioresorbable Vascular Scaffold Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Application
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 10.3.1. India
    • 10.3.2. Southeast Asia
    • 10.3.3. ANZ
    • 10.3.4. Rest of South Asia & Oceania
  • 10.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Product, 2024-2031
    • 10.4.1. Metal Bioresorbable Vascular Scaffold
    • 10.4.2. Polymer Bioresorbable Vascular Scaffold
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
    • 10.5.1. Peripheral Artery
    • 10.5.2. Coronary Artery
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 10.6.1. Hospitals
    • 10.6.2. Ambulatory Care Centers
    • 10.6.3. Cardiac Centers
    • 10.6.4. Others
  • 10.7. Market Attractiveness Analysis

11. Latin America Bioresorbable Vascular Scaffold Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Application
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 11.3.1. Brazil
    • 11.3.2. Mexico
    • 11.3.3. Rest of Latin America
  • 11.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Product, 2024-2031
    • 11.4.1. Metal Bioresorbable Vascular Scaffold
    • 11.4.2. Polymer Bioresorbable Vascular Scaffold
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
    • 11.5.1. Peripheral Artery
    • 11.5.2. Coronary Artery
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 11.6.1. Hospitals
    • 11.6.2. Ambulatory Care Centers
    • 11.6.3. Cardiac Centers
    • 11.6.4. Others
  • 11.7. Market Attractiveness Analysis

12. Middle East & Africa Bioresorbable Vascular Scaffold Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 12.1. Key Highlights
  • 12.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 12.2.1. By Country
    • 12.2.2. By Product
    • 12.2.3. By Application
    • 12.2.4. By End User
  • 12.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 12.3.1. GCC Countries
    • 12.3.2. Egypt
    • 12.3.3. South Africa
    • 12.3.4. Northern Africa
    • 12.3.5. Rest of Middle East & Africa
  • 12.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Product, 2024-2031
    • 12.4.1. Metal Bioresorbable Vascular Scaffold
    • 12.4.2. Polymer Bioresorbable Vascular Scaffold
  • 12.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
    • 12.5.1. Peripheral Artery
    • 12.5.2. Coronary Artery
  • 12.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 12.6.1. Hospitals
    • 12.6.2. Ambulatory Care Centers
    • 12.6.3. Cardiac Centers
    • 12.6.4. Others
  • 12.7. Market Attractiveness Analysis

13. Competition Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. Market Structure
    • 13.2.1. Competition Intensity Mapping By Market
    • 13.2.2. Competition Dashboard
  • 13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 13.3.1. Meril Life Sciences Pvt. Ltd.
      • 13.3.1.1. Overview
      • 13.3.1.2. Segments and Products
      • 13.3.1.3. Key Financials
      • 13.3.1.4. Market Developments
      • 13.3.1.5. Market Strategy
    • 13.3.2. Zeus Company LLC
    • 13.3.3. Biotronik
    • 13.3.4. Abbott
    • 13.3.5. MicroPort Scientific Corporation
    • 13.3.6. Kyoto Medical
    • 13.3.7. Elixir Medical (MedImpact Healthcare Systems, Inc.)
    • 13.3.8. Cigna
    • 13.3.9. B. Braun Melsungen AG
    • 13.3.10. Boston Scientific Corporation
    • 13.3.11. REVA Medical

14. Appendix

  • 14.1. Research Methodology
  • 14.2. Research Assumptions
  • 14.3. Acronyms and Abbreviations
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦